Simris Alg AB (publ) Total Liabilities

Latest as of June 2026: Skr136.97 Million SEK ≈ $14.74 Million USD

Simris Alg AB (publ) total liabilities. Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has total liabilities worth Skr136.97 Million SEK (≈ $14.74 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See SIMRIS-B defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Simris Alg AB (publ) (2012–2025)

Total liabilities of Simris Alg AB (publ) from 2012 to 2025. This chart illustrates how Simris Alg AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.

Simris Alg AB (publ) Competitors by Total Liabilities

The table below lists competitors of Simris Alg AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Theta Edge Bhd
KLSE:9075
Malaysia RM43.41 Million
Hawthorn Resources Ltd
AU:HAW
Australia AU$1.59 Million
Pinehill Pacific Bhd
KLSE:1902
Malaysia RM-7.95 Million
Korea SPAC 2
KQ:206400
Korea ₩5.85 Billion
Big Digital Energy, Inc.
NASDAQ:BGDE
USA $60.56 Million
Calgro M3 Holdings Ltd
JSE:CGR
South Africa ZAC1.96 Billion
Nexen Tire Prf 1
KO:002355
Korea ₩2.95 Trillion

Liability Composition Analysis (2012–2025)

This chart breaks down Simris Alg AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Simris Alg AB (publ) total assets.

Liquidity & Leverage Metrics

Simris Alg AB (publ) Total Liabilities Ratios Explained

Simris Alg AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.81 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 178.57 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.99 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Simris Alg AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Simris Alg AB (publ) (2012–2025)

The table below shows the annual total liabilities of Simris Alg AB (publ) from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr148.85 Million
≈ $16.02 Million
-1.69%
2024-12-31 Skr151.42 Million
≈ $16.29 Million
+1.66%
2023-12-31 Skr148.94 Million
≈ $16.03 Million
-8.45%
2022-12-31 Skr162.68 Million
≈ $17.51 Million
+1381.58%
2021-12-31 Skr10.98 Million
≈ $1.18 Million
+13.88%
2020-12-31 Skr9.64 Million
≈ $1.04 Million
-43.98%
2019-12-31 Skr17.21 Million
≈ $1.85 Million
+71.18%
2018-12-31 Skr10.05 Million
≈ $1.08 Million
-14.11%
2017-12-31 Skr11.71 Million
≈ $1.26 Million
+6.13%
2016-12-31 Skr11.03 Million
≈ $1.19 Million
-34.90%
2015-12-31 Skr16.94 Million
≈ $1.82 Million
+1461.47%
2014-12-31 Skr1.08 Million
≈ $116.76K
+54.44%
2013-12-31 Skr702.52K
≈ $75.60K
+10.93%
2012-12-31 Skr633.30K
≈ $68.15K
--

About Simris Alg AB (publ)

ST:SIMRIS-B Sweden Biotechnology
Market Cap
$17.29 Million
Skr160.63 Million SEK
Market Cap Rank
#25411 Global
#509 in Sweden
Share Price
Skr0.12
Change (1 day)
+5.31%
52-Week Range
Skr0.04 - Skr0.17
All Time High
Skr14.17
About

Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more